BNGO vs. AATC, CLIR, MSAI, DAIO, STAI, PRPO, ASTC, TLIS, AXDX, and TBIO
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Autoscope Technologies (AATC), ClearSign Technologies (CLIR), MultiSensor AI (MSAI), Data I/O (DAIO), Scantech AI Systems (STAI), Precipio (PRPO), Astrotech (ASTC), Talis Biomedical (TLIS), Accelerate Diagnostics (AXDX), and Telesis Bio (TBIO). These companies are all part of the "measuring and control equipment" industry.
Bionano Genomics vs.
Autoscope Technologies (NASDAQ:AATC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
Autoscope Technologies has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.
Bionano Genomics has a consensus price target of $7.00, indicating a potential upside of 90.74%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Autoscope Technologies.
Autoscope Technologies has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Autoscope Technologies, indicating that it is currently the more affordable of the two stocks.
11.4% of Bionano Genomics shares are owned by institutional investors. 21.6% of Autoscope Technologies shares are owned by company insiders. Comparatively, 0.9% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Bionano Genomics received 164 more outperform votes than Autoscope Technologies when rated by MarketBeat users. Likewise, 63.81% of users gave Bionano Genomics an outperform vote while only 0.00% of users gave Autoscope Technologies an outperform vote.
Autoscope Technologies has a net margin of 37.59% compared to Bionano Genomics' net margin of -407.34%. Autoscope Technologies' return on equity of 27.06% beat Bionano Genomics' return on equity.
In the previous week, Bionano Genomics had 1 more articles in the media than Autoscope Technologies. MarketBeat recorded 2 mentions for Bionano Genomics and 1 mentions for Autoscope Technologies. Autoscope Technologies' average media sentiment score of 0.00 beat Bionano Genomics' score of -1.00 indicating that Autoscope Technologies is being referred to more favorably in the media.
Summary
Autoscope Technologies and Bionano Genomics tied by winning 9 of the 18 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:BNGO) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy BNGO Stock Free BNGO Stock Alerts